Portfolio
High Technology.
Real Healthcare Impact.
MedicAlgorithmics
A medical technology company specializing in cardiology, offering FDA-cleared AI-based software and diagnostic devices. In 2022 it performed 170,000 cardiac tests worldwide and is publicly traded, with BioFund as its major shareholder.
Holo Surgical Inc.
A medical technology company developing an FDA-certified, AI- and Augmented Reality-based surgical guidance system. The platform supports surgeons—and ultimately surgical robots—in performing procedures with greater precision, safety, and efficiency.
Inteneural Networks
A developer of advanced AI and Machine Learning applications for brain diagnostics. Its technology analyzes complex neurological data in minutes, automating tasks that would normally require hours of expert work and enabling earlier, more accurate detection of critical conditions.
Kardiolytics
A medical technology company developing AI-powered diagnostics that make advanced cardiac assessment affordable and widely accessible. Its platform extracts critical information about blood vessel narrowing from standard CT scans, replacing complex, invasive, and costly procedures with a fast, non-invasive alternative.
Dystrogen Therapeutics
A clinical-stage biotechnology company focused on cell therapies for rare diseases. It is currently conducting human trials of its Dystrophin Expressing Chimeric (DEC) therapy for Duchenne Muscular Dystrophy, a severe genetic condition that progressively weakens the muscular system.
MultiQure
A life sciences company developing innovative treatments for rare genetic neurodegenerative disorders. Its lead therapeutic candidate targets Huntington’s Disease and has demonstrated highly promising results in pre-clinical studies.
Versa Vascular
Established in 2020, Versa Vascular came out of Santa Cruz MedTech incubator called Occam Labs. The founding team combined their collective expertise in structural heart catheters and implants to tackle the large unmet need to treat those suffering with Tricuspid disease.
Capstan Medical
Is commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, Capstan Medical pioneered a patient-optimized approach to repair and replace heart valves. SV is a seed stage investor.